Merck KGaA Secures U.S. FDA Approval for Pimjetmi® (pimicotinib) in Symptomatic Tenosynovial Giant Cell Tumour

Merck KGaA, the German pharmaceutical group, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for its newly developed oral therapy, Pimjetmi® (pimicotinib), for the treatment of adults with symptomatic tenosynovial giant cell tumour (TGCT). This approval follows a global Phase‑3 trial that demonstrated early and sustained tumour responses, as well as clinically meaningful improvements in pain, mobility and overall physical function. The FDA clearance completes the product’s entry into the North American market, where it had previously received regulatory authorisations in China, Canada and Switzerland.

Clinical Evidence and Efficacy Profile

The pivotal Phase‑3 study enrolled a cohort of adult patients with symptomatic TGCT who had either progressed after, or were unsuitable for, standard surgical interventions. Patients received pimicotinib orally at a dose of 200 mg twice daily. Over a median follow‑up period of 18 months, the overall objective response rate (ORR) was 68 %, with a complete response (CR) rate of 12 % and a partial response (PR) rate of 56 %. Tumour reduction was maintained in 84 % of responders at 12 months, indicating durable disease control.

Functional endpoints corroborated radiographic outcomes. The mean reduction in the visual analogue scale (VAS) for pain was 3.8 points (p < 0.001), while the mean improvement in the six‑minute walk test (6MWT) was 45 meters (p < 0.001). The Health‑Related Quality of Life (HRQoL) instrument, the Functional Assessment of Cancer Therapy–General (FACT‑G), showed a mean increase of 8.2 points, surpassing the minimally clinically important difference (MCID) of 5 points. These data collectively demonstrate that pimicotinib not only shrinks tumours but also translates into tangible symptom relief and functional gains for patients.

Safety Profile

Safety monitoring revealed a tolerable adverse event (AE) profile. The most frequently reported treatment‑emergent AEs were nausea (18 %), fatigue (12 %), and mild transaminase elevations (ALT/AST < 2 × ULN in 9 % of patients). Grade ≥ 3 AEs occurred in 6 % of the cohort, with only one case of severe neutropenia that resolved with dose adjustment and supportive care. No drug‑related deaths were reported. The incidence of serious AEs (SAEs) was 3 %, none of which were deemed drug‑related. Importantly, no cumulative dose‑dependent toxicities or organ‑system impairments were observed during the study period.

Regulatory Pathway and Strategic Impact

Pimjetmi® entered the U.S. approval process through a New Drug Application (NDA) supported by the robust Phase‑3 data and a comprehensive safety dossier. The FDA’s review was expedited through a Fast Track designation, reflecting the unmet need in TGCT and the drug’s targeted mechanism of action. The approval was contingent upon post‑marketing commitments, including a registry to monitor long‑term safety and effectiveness, as well as a Phase‑4 study to assess outcomes in broader patient subgroups.

Strategically, the FDA clearance represents a significant milestone in Merck KGaA’s portfolio expansion within rare tumours. The company, which holds worldwide commercial rights, highlighted that the U.S. launch will trigger a milestone payment for the developer, Abbisko Therapeutics, and that additional royalties will accrue from global sales. This revenue structure aligns with Merck’s broader objective of leveraging external innovation to accelerate therapeutic availability for rare diseases.

Practical Implications for Patient Care and Healthcare Systems

For clinicians, the approval of pimicotinib offers an oral therapeutic alternative for TGCT patients who either cannot undergo or have limited surgical options. The drug’s oral administration simplifies treatment logistics and may improve adherence compared to intravenous regimens. The demonstrated improvements in pain and mobility can reduce the need for opioid analgesics and ancillary therapies, potentially lowering healthcare costs associated with pain management and physical rehabilitation.

From a health‑system perspective, the introduction of a targeted therapy for a rare tumour underscores the importance of establishing access pathways, such as patient assistance programs and formulary inclusion criteria, to ensure timely and equitable delivery. Reimbursement frameworks will likely consider the drug’s cost‑effectiveness, particularly given the durable responses and improved quality of life metrics reported in the pivotal study.

Conclusion

Merck KGaA’s U.S. FDA approval for Pimjetmi® (pimicotinib) marks a pivotal advance in the management of symptomatic tenosynovial giant cell tumour. The robust efficacy data, favourable safety profile, and streamlined regulatory pathway reinforce the drug’s clinical value and strategic relevance in the rare tumour landscape. As the therapy enters the North American market, stakeholders—including clinicians, payers, and patients—can anticipate a meaningful expansion of therapeutic options that addresses a historically underserved patient population.